Sugi Predict

Sugi Predict / Compounds / SCHEMBL288609

SCHEMBL288609

SCHEMBL288609

CCC(C)[C@H](NC)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ FPR2 P25090 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ MME P08473 2/20 0.42
▸ ACE P12821 2/20 0.42
▸ CPA1 P15085 2/20 0.42
▸ ACE2 Q9BYF1 2/20 0.42
▸ CA2 P00918 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ ENPEP Q07075 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203221 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL203222 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL2034664 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL2034259 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL43380 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL43381 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL18560091 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
Hydrochloric Acid SCHEMBL17113018 0.98 ALDH1A1 (0.57) ALDH1A1L3MBTL1FPR2MEN1KMT2A
Hydrochloric Acid SCHEMBL17113020 0.98 ALDH1A1 (0.57) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL12611984 0.92 ALDH1A1 (0.52) ALDH1A1L3MBTL1FPR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114686537-A Method for producing N-methyl-L-amino acid by catalyzing L-amino acid through multi-enzyme cascade and application thereof 华南理工大学 2022-07-01 — — CN claimed
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 — — US claimed
WO-2017092759-A1 GEPHYRIN BINDING PEPTIDES AND USES THEREOF UNIVERSITY OF COPENHAGEN (DK) 2017-06-08 — — WO claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 — — EP claimed
US-20130046077-A1 DOLASTATIN 15 DERIVATIVES ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2013-02-21 — — US claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 — — US claimed
US-8163698-B2 Dolastatin 15 derivatives ABBOTT GMBH & CO. KG (DE) 2012-04-24 — — US claimed
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO. KG (DE) 2010-04-22 — — US claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 — — US claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 — — US claimed
CN-1391577-A Pharmaceutical compositions comprising metal complexes ANORMED INC (CA) 2003-01-15 — — CN claimed
US-20020155565-A1 FAP-activated anti-tumor compounds BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-24 — — US claimed
US-6458781-B1 BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS WARNER-LAMBERT COMPANY 2002-10-01 — — US claimed
WO-1999055688-A1 SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-11-04 — — WO claimed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 — — EP disclosed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 — — US disclosed
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) 2026-03-12 — — US disclosed
US-4342751-A Majusculamide C ELI LILLY AND COMPANY (US) 1982-08-03 — — US disclosed
US-4118482-A Process for treating neoplastic disease with azetomicins THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1978-10-03 — — US disclosed
US-4053460-A ACTINOMYCIN ANTIBIOTIC ANALOGUES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1977-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS HTR2B, MC1R, HTR1A ALDH1A1 4268/4885L3MBTL1 3373/4885FPR2 175/4885
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES DDOST, DBI, DAO ALDH1A1 1830/4885L3MBTL1 1315/4885FPR2 726/4885
US-20020155565-A1 FAP-activated anti-tumor compounds FAP, FIBP, DNPEP ALDH1A1 1638/4885L3MBTL1 2451/4885FPR2 761/4885
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CXCR4, CXCR2, GRPR ALDH1A1 1068/4885L3MBTL1 2378/4885FPR2 121/4885
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, FCGR1A, FCGR2A ALDH1A1 3922/4885L3MBTL1 145/4885FPR2 461/4885
US-20130046077-A1 DOLASTATIN 15 DERIVATIVES DDOST, DBI, DAO ALDH1A1 1830/4885L3MBTL1 1315/4885FPR2 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.